NLRP3 and metabolic dysfunction-associated steatohepatitis: Furthermore, these SPMs have been shown to modulate the NLRP3 inflammasome pathway and reduce IL-1β expression and secretion in several inflammatory models such as in vitro LPS-induced primary human blood monocytes, THP-1 monocytic cells [69], oxidative stress-induced THP-1 macrophages [70], and in animal models of burn wounds [71], post-myocardial infarction [72], high-fat obesity [73], and NASH [74].